H1N1 Products Already Boosting Bottom Line For McKesson
Executive Summary
As drug companies prepare vaccines to address the H1N1 virus, pharmaceutical wholesaler McKesson already is seeing a positive effect on its bottom line from products related to controlling the virus
You may also be interested in...
No Health Care Reform? No Problem For Wholesalers
A strong quarter by the three major drug wholesalers shows the industry is in strong shape with or without health care reform, AmerisourceBergen CEO David Yost said
No Health Care Reform? No Problem For Wholesalers
A strong quarter by the three major drug wholesalers shows the industry is in strong shape with or without health care reform, AmerisourceBergen CEO David Yost said
H1N1 Vaccine Trials: NIH Will Mix And Match Antigens, Adjuvants
The National Institutes of Health is developing a plan B as H1N1 vaccine manufacturers race to produce enough product by the start of flu season. The agency is going to mix and match antigen and adjuvant from different sponsors to try to find the best immunogenicity